Figure S2. Intracerebroventricularly administered DMSO has no significant effect on audiogenic
seizure sensitivity.
Groups of approximately 15 FX and wt male mice (FVB strain; from left to right, n = 15, 14, 16,
and 15) were given icv DMSO in the volumes listed 30 minutes prior to AGS testing either once
at 30 days of age (“1x”), or once daily beginning at 26 days of age for 5 days (“5x”). The
percentages of mice exhibiting audiogenic seizures (“AGS”) were compared by chi-square
analysis.
Figure S3. Intraperitoneal administration of GSK3 inhibitor SB-216763 and mGluR5 antagonist
MPEP: no statistically significant difference between SB + MPEP and MPEP alone.
Groups of 15 male FX mice on FVB/NJ or “HYB” (C57BL/6J x FVB/NJ) backgrounds were
given ip injections of SB-216763 (“SB”), MPEP, or vehicle (DMSO) in the doses and volumes
indicated in the legend. Statistical significance was assessed by one factor ANOVA followed by
Tukey-Kramer HSD test. * p<0.05; **p<0.01; ***p<0.001.
Supplemental Figures